- TOP
- NEWS
- New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good
New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good
Agreement Worth Potentially 5 Billion Yen for the VR Healthcare Market
Jolly Good Inc. and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director: Makoto Inoue) have signed an agreement for exclusive product joint development and sales in Japan for a social skill training VR (“SST VR”) business. If including a 300 millon yen upfront payment from Otsuka Pharmaceutical to Jolly Good, as well as development cost reimbursement and royalties, the deal is worth 5 billion yen.